FR2462431B1 - Nouveau compose du guanidinothiazole, son procede de preparation et des compositions medicales contenant de tels composes - Google Patents

Nouveau compose du guanidinothiazole, son procede de preparation et des compositions medicales contenant de tels composes

Info

Publication number
FR2462431B1
FR2462431B1 FR797931938A FR7931938A FR2462431B1 FR 2462431 B1 FR2462431 B1 FR 2462431B1 FR 797931938 A FR797931938 A FR 797931938A FR 7931938 A FR7931938 A FR 7931938A FR 2462431 B1 FR2462431 B1 FR 2462431B1
Authority
FR
France
Prior art keywords
novel
compounds
compositions containing
preparing same
medical compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
FR797931938A
Other languages
English (en)
Other versions
FR2462431A1 (fr
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yamanouchi Pharmaceutical Co Ltd
Original Assignee
Yamanouchi Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=14232166&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR2462431(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Yamanouchi Pharmaceutical Co Ltd filed Critical Yamanouchi Pharmaceutical Co Ltd
Publication of FR2462431A1 publication Critical patent/FR2462431A1/fr
Application granted granted Critical
Publication of FR2462431B1 publication Critical patent/FR2462431B1/fr
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/44—Acylated amino or imino radicals
    • C07D277/48—Acylated amino or imino radicals by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof, e.g. carbonylguanidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/40—Unsubstituted amino or imino radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
FR797931938A 1979-08-02 1979-12-28 Nouveau compose du guanidinothiazole, son procede de preparation et des compositions medicales contenant de tels composes Expired FR2462431B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP54098906A JPS6056143B2 (ja) 1979-08-02 1979-08-02 アミジン誘導体ならびにその製造法

Publications (2)

Publication Number Publication Date
FR2462431A1 FR2462431A1 (fr) 1981-02-13
FR2462431B1 true FR2462431B1 (fr) 1985-07-26

Family

ID=14232166

Family Applications (1)

Application Number Title Priority Date Filing Date
FR797931938A Expired FR2462431B1 (fr) 1979-08-02 1979-12-28 Nouveau compose du guanidinothiazole, son procede de preparation et des compositions medicales contenant de tels composes

Country Status (12)

Country Link
US (1) US4283408A (fr)
JP (1) JPS6056143B2 (fr)
CA (2) CA1134836A (fr)
CH (1) CH648027A5 (fr)
DE (1) DE2951675C2 (fr)
ES (1) ES8100281A1 (fr)
FR (1) FR2462431B1 (fr)
GB (1) GB2055800B (fr)
IT (1) IT1119641B (fr)
NL (2) NL180420C (fr)
PH (1) PH15657A (fr)
SE (1) SE444317B (fr)

Families Citing this family (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA782129B (en) * 1977-04-20 1979-03-28 Ici Ltd Hertocyclic derivatives
PH16099A (en) * 1979-03-06 1983-06-24 Yamanouchi Pharma Co Ltd Guanidinothiazole compounds,process for preparing them and medical composition containing them
GR71929B (fr) * 1979-11-13 1983-08-19 Ici Ltd
DE3168031D1 (en) * 1980-07-30 1985-02-14 Ici Plc Guanidine derivatives
US4382090A (en) * 1980-10-02 1983-05-03 Eli Lilly And Company N-Thiazolylmethylthioalkyl-N'alkylamidines and related compounds
IN158869B (fr) * 1981-03-18 1987-02-07 Ici Plc
DE3267110D1 (de) * 1981-05-18 1985-12-05 Ici Plc Amidine derivatives
DE3238867A1 (de) * 1982-10-20 1984-04-26 Ludwig Heumann & Co GmbH, 8500 Nürnberg Heterocyclische verbindungen, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
JPS59104370A (ja) * 1982-12-03 1984-06-16 Kotobuki Seiyaku Kk チアゾ−ル誘導体及びその製造方法
JPS59227870A (ja) * 1983-06-07 1984-12-21 Yamanouchi Pharmaceut Co Ltd 新規２−グアニジノチアゾリン誘導体ならびにその製造法
US4497810A (en) * 1983-10-14 1985-02-05 Merck & Co., Inc. Thiatriazine dioxides as gastric anti-secretory agents
US4663347A (en) 1983-10-31 1987-05-05 Merck Frosst Canada, Inc. Benzofuran 2-carboxylic acid esters useful as inhibitors of leukotriene biosynthesis
CA1269382A (fr) * 1984-04-18 1990-05-22 Jose A. Ortiz Sulfonamidines anti-ulcereuses
US4560690A (en) * 1984-04-30 1985-12-24 Pfizer Inc. 2-(N-substituted guanidino)-4-hetero-arylthiazole antiulcer agents
JPS6160673A (ja) * 1984-08-30 1986-03-28 Yamanouchi Pharmaceut Co Ltd グアニジノチアゾ−ル誘導体の製造法
CA1309557C (fr) 1985-06-18 1992-10-27 Robert N. Young Antagonistes de leucotrienes
HU194845B (en) * 1985-09-11 1988-03-28 Richter Gedeon Vegyeszet Process for production of n-sulphamil-3-/2-guanidintiazolil-4-methil-tio/-propion-amidin
DE3786030T2 (de) 1986-03-27 1993-12-02 Merck Frosst Canada Inc Tetrahydrocarbazole Ester.
DE3644246A1 (de) * 1986-06-20 1987-12-23 Uriach & Cia Sa J Verfahren zur herstelung von 3-(((2-((aminoiminomethyl)-amino)-4-thiazolyl)-methyl)-thio)-n-(aminosulfonyl)-propanimidamid
HU196775B (en) * 1986-08-05 1989-01-30 Richter Gedeon Vegyeszet Process for production of morfologically unique new modifications of famotidin and medical compositions containing such substances
ES2008810A6 (es) * 1988-07-18 1989-08-01 Marga Investigacion Procedimiento de preparacion de derivados de n-sulfamil-propionamidina.
HUT61980A (en) 1990-10-12 1993-03-29 Merck Frosst Canada Inc Process for producing saturated hydroxyalkylquinoline acids and pharmaceutical compositions comprising such compounds as active ingredient
US5294433A (en) * 1992-04-15 1994-03-15 The Procter & Gamble Company Use of H-2 antagonists for treatment of gingivitis
CA2110313C (fr) * 1992-12-01 2004-10-26 Edward John Roche Compositions pharmaceutiques contenant un compose de guanidothiazole et antiacides
US5410054A (en) * 1993-07-20 1995-04-25 Merck Frosst Canada, Inc. Heteroaryl quinolines as inhibitors of leukotriene biosynthesis
US5593696A (en) * 1994-11-21 1997-01-14 Mcneil-Ppc, Inc. Stabilized composition of famotidine and sucralfate for treatment of gastrointestinal disorders
US5650421A (en) * 1995-03-31 1997-07-22 Baxter International Inc. Premixed famotidine formulation
US5667794A (en) * 1995-05-02 1997-09-16 Merck & Co., Inc. Heartburn treatment
US5854267A (en) * 1995-06-02 1998-12-29 Merck & Co., Inc. Method for preventing heartburn
KR0168978B1 (ko) * 1995-07-12 1999-01-15 김종인 헤테로고리 접합 티아졸 유도체
US5989588A (en) * 1996-10-04 1999-11-23 Merck & Co., Inc. Methods and compositions for preventing and treating heartburn
US6949264B1 (en) 1996-11-27 2005-09-27 Wm. Wrigley Jr. Company Nutraceuticals or nutritional supplements and method of making
US5856500A (en) * 1997-03-11 1999-01-05 Albemarle Corporation Synthesis of thiazole derivatives
US5731442A (en) * 1997-03-11 1998-03-24 Albemarle Corporation Synthesis of thiazole derivatives
US6552047B2 (en) * 1998-11-17 2003-04-22 Nitromed, Inc. H2 receptor antagonist compounds in combination with nitric oxide donors, compositions and methods of use
US7163705B2 (en) 1998-12-15 2007-01-16 Wm. Wrigley Jr. Company Coated chewing gum product and method of making
US6531114B1 (en) 1999-04-06 2003-03-11 Wm. Wrigley Jr. Company Sildenafil citrate chewing gum formulations and methods of using the same
US6586023B1 (en) 1998-12-15 2003-07-01 Wm. Wrigley Jr. Company Process for controlling release of active agents from a chewing gum coating and product thereof
US6627234B1 (en) 1998-12-15 2003-09-30 Wm. Wrigley Jr. Company Method of producing active agent coated chewing gum products
US6270807B1 (en) 1999-03-02 2001-08-07 L. Perrigo Company Taste-masked pharmaceutical composition
US6322806B1 (en) 1999-04-06 2001-11-27 Wm. Wrigley Jr. Company Over-coated chewing gum formulations including tableted center
US6773716B2 (en) 1999-04-06 2004-08-10 Wm. Wrigley Jr. Company Over-coated chewing gum formulations
US7935362B2 (en) 1999-04-06 2011-05-03 Wm. Wrigley Jr. Company Over-coated product including consumable center and medicament
AU784112B2 (en) * 1999-04-06 2006-02-09 Wm. Wrigley Jr. Company Pharmaceutical chewing gum formulations
US6355265B1 (en) 1999-04-06 2002-03-12 Wm. Wrigley Jr. Company Over-coated chewing gum formulations
US6569472B1 (en) 2000-09-01 2003-05-27 Wm. Wrigley Jr. Company Coated chewing gum products containing antacid and method of making
US6645535B2 (en) 1999-09-02 2003-11-11 Wm. Wrigley Jr. Company Method of making coated chewing gum products containing various antacids
US6663849B1 (en) 2000-09-01 2003-12-16 Wm. Wrigley Jr. Company Antacid chewing gum products coated with high viscosity materials
US6541048B2 (en) 1999-09-02 2003-04-01 Wm. Wrigley Jr. Company Coated chewing gum products containing an acid blocker and process of preparing
US9387168B2 (en) 1999-09-20 2016-07-12 Jack Barreca Chewing gum with tomatidine
AU3885201A (en) 1999-09-20 2001-04-24 Mastercare Diet and weight control gum and sucker
US9253991B2 (en) 1999-09-20 2016-02-09 Jack Barreca Chewing gum with B vitamins
US7115288B2 (en) 2000-06-09 2006-10-03 Wm. Wrigley Jr. Company Method for making coated chewing gum products with a coating including an aldehyde flavor and a dipeptide sweetener
US6572900B1 (en) 2000-06-09 2003-06-03 Wm. Wrigley, Jr. Company Method for making coated chewing gum products including a high-intensity sweetener
US6444241B1 (en) 2000-08-30 2002-09-03 Wm. Wrigley Jr. Company Caffeine coated chewing gum product and process of making
US6579545B2 (en) 2000-12-22 2003-06-17 Wm. Wrigley Jr. Company Coated chewing gum products containing an antigas agent
SE0101379D0 (sv) * 2001-04-18 2001-04-18 Diabact Ab Komposition som hämmar utsöndring av magsyra
SE0203065D0 (sv) 2002-10-16 2002-10-16 Diabact Ab Gastric acid secretion inhibiting composition
TW200517114A (en) 2003-10-15 2005-06-01 Combinatorx Inc Methods and reagents for the treatment of immunoinflammatory disorders
EP1579862A1 (fr) 2004-03-25 2005-09-28 Boehringer Ingelheim Vetmedica Gmbh Utilisation des inhibiteurs de PDE III pour la réduction de la taille du coeur chez des mammifères souffrant d'insufficances cardiaques
US8980894B2 (en) 2004-03-25 2015-03-17 Boehringer Ingelheim Vetmedica Gmbh Use of PDE III inhibitors for the treatment of asymptomatic (occult) heart failure
US20080045575A1 (en) * 2004-12-29 2008-02-21 Van Dyke Thomas E Delivery of H2 Antagonists
US20080021078A1 (en) * 2006-07-18 2008-01-24 Horizon Therapeutics, Inc. Methods and medicaments for administration of ibuprofen
US20070043096A1 (en) * 2005-07-18 2007-02-22 Horizon Therapeutics, Inc. Unit dose form with ibuprofen-famotidine admixture
US8067451B2 (en) * 2006-07-18 2011-11-29 Horizon Pharma Usa, Inc. Methods and medicaments for administration of ibuprofen
US20080020040A1 (en) * 2006-07-18 2008-01-24 Horizon Therapeutics, Inc. Unit dose form for administration of ibuprofen
BRPI0618643A2 (pt) 2005-11-09 2011-09-06 Combinatorx Inc composição compreendendo um par de fármacos, composição compreendendo um corticosteróide e um imunossupressor dependente de imunofilina não-esteróide, kits e uso
US8067033B2 (en) 2007-11-30 2011-11-29 Horizon Pharma Usa, Inc. Stable compositions of famotidine and ibuprofen
ATE539747T1 (de) 2006-07-18 2012-01-15 Horizon Therapeutics Inc Verfahren und medikamente zur verabreichung von ibuprofen
WO2008027963A2 (fr) * 2006-08-31 2008-03-06 Horizon Therapeutics, Inc. Formulations à dose unique d'ains avec antagonistes du récepteur de h2, et procédés d'utilisation
EP1920785A1 (fr) 2006-11-07 2008-05-14 Boehringer Ingelheim Vetmedica Gmbh Préparation liquide contenant un complexe du pimobendane et de la cyclodextrine
US8039461B1 (en) 2006-11-10 2011-10-18 Pisgah Laboratories, Inc. Physical states of a pharmaceutical drug substance
US7718649B1 (en) 2006-11-10 2010-05-18 Pisgah Labs, Inc. Physical states of a pharmaceutical drug substance
US20090069395A1 (en) * 2007-09-09 2009-03-12 Protia, Llc Deuterium-enriched famotidine
CA2956278C (fr) * 2008-01-04 2022-03-01 Schabar Research Associates Llc Compositions de doses buccales unitaires composees d'ibuprofene et de famotidine, et applications connexes
US8883863B1 (en) 2008-04-03 2014-11-11 Pisgah Laboratories, Inc. Safety of psuedoephedrine drug products
WO2010021681A2 (fr) * 2008-08-18 2010-02-25 Combinatorx (Singapore) Pte. Ltd. Compositions et procédés pour le traitement de maladies virales
TW201105233A (en) 2009-05-11 2011-02-16 Agraquest Inc Compounds derived from muscodor fungi
US20110130711A1 (en) * 2009-11-19 2011-06-02 Follica, Inc. Hair growth treatment
HUE060093T2 (hu) 2012-03-15 2023-01-28 Boehringer Ingelheim Vetmedica Gmbh Gyógyszerészeti tablettakészítmény az állatgyógyászati ágazat számára, eljárás annak elõállítására és annak alkalmazása
JP6378179B2 (ja) * 2013-07-03 2018-08-22 株式会社新日本科学 新規化合物，有機カチオントランスポーター３の検出剤及び活性阻害剤
PL3021832T3 (pl) 2013-07-19 2021-08-23 Boehringer Ingelheim Vetmedica Gmbh Konserwowana ciekła wodna kompozycja farmaceutyczna zawierająca eteryfikowane pochodne cyklodekstryny
DK2925305T3 (en) 2013-12-04 2016-10-10 Boehringer Ingelheim Vetmedica Gmbh Improved pharmaceutical compositions of pimobendan.
WO2015155297A1 (fr) 2014-04-11 2015-10-15 Sanovel Ilac Sanayi Ve Ticaret A.S. Combinaisons pharmaceutiques de dabigatran et d'antagonistes du récepteur h2
WO2015163832A1 (fr) 2014-04-25 2015-10-29 Pharmacti̇ve İlaç Sanayi̇ Ve Ti̇caret A.Ş. Composition combinée d'ibuprofène et de famotidine ayant une stabilité améliorée
WO2015169957A1 (fr) 2014-05-09 2015-11-12 Sanovel Ilac Sanayi Ve Ticaret A.S. Combinaisons pharmaceutiques de rivaroxaban et d'antagonistes du récepteur h2
US10537570B2 (en) 2016-04-06 2020-01-21 Boehringer Ingelheim Vetmedica Gmbh Use of pimobendan for the reduction of heart size and/or the delay of onset of clinical symptoms in patients with asymptomatic heart failure due to mitral valve disease
TR201618765A2 (tr) 2016-12-16 2018-07-23 Imuneks Farma Ilac Sanayi Ve Ticaret Anonim Sirketi Ağrı ve enflamasyonun tedavisi için steroid olmayan anti-enflamatuvar ilaçlar ve H2 reseptörü antagonisti kombinasyonları.
KR20230051164A (ko) 2020-07-15 2023-04-17 샤바르 리서치 어소시에이츠 엘엘씨 급성 통증의 치료 및 속쓰림의 중증도 및/또는 위험의 감소를 위한 이부프로펜 및 파모티딘으로 구성된 단위 경구 투여 조성물
US11324727B2 (en) 2020-07-15 2022-05-10 Schabar Research Associates, Llc Unit oral dose compositions composed of naproxen sodium and famotidine for the treatment of acute pain and the reduction of the severity of heartburn and/or the risk of heartburn
EP4196793A1 (fr) 2020-08-11 2023-06-21 Université de Strasbourg Bloqueurs de h2 ciblant des macrophages du foie pour la prévention et le traitement d'une maladie du foie et du cancer

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1338169A (en) * 1971-03-09 1973-11-21 Smith Kline French Lab Ureas thioureas and guanidines
ZA782129B (en) * 1977-04-20 1979-03-28 Ici Ltd Hertocyclic derivatives
US4165378A (en) * 1977-04-20 1979-08-21 Ici Americas Inc. Guanidine derivatives of imidazoles and thiazoles

Also Published As

Publication number Publication date
IT1119641B (it) 1986-03-10
SE7910568L (sv) 1981-02-03
NL180420B (nl) 1986-09-16
NL930038I1 (nl) 1993-08-02
GB2055800B (en) 1983-05-11
JPS6056143B2 (ja) 1985-12-09
PH15657A (en) 1983-03-11
NL7909321A (nl) 1981-02-04
CH648027A5 (de) 1985-02-28
GB2055800A (en) 1981-03-11
DE2951675C2 (de) 1982-07-01
CA1222763B (fr) 1987-06-09
CA1134836A (fr) 1982-11-02
DE2951675A1 (de) 1981-02-05
ES487381A0 (es) 1980-11-01
FR2462431A1 (fr) 1981-02-13
NL930038I2 (nl) 1993-10-01
NL180420C (nl) 1987-02-16
SE444317B (sv) 1986-04-07
ES8100281A1 (es) 1980-11-01
US4283408A (en) 1981-08-11
JPS5622770A (en) 1981-03-03
IT7969498A0 (it) 1979-12-28

Similar Documents

Publication Publication Date Title
FR2462431B1 (fr) Nouveau compose du guanidinothiazole, son procede de preparation et des compositions medicales contenant de tels composes
DE3060592D1 (en) Derivatives of 2,4,6-triodo-isophthalic acid, process for their preparation and x-ray contrast agents containing them
DE3072122D1 (en) 7-acylamino-3-vinylcephalosporanic acid derivatives, processes for their preparation, pharmaceutical compositions containing them; their starting compounds and their preparation
MY8500062A (en) 1,2,4-troazome deriovatives, process for preparing such compounds and pharmaceutical compositions containing them
DE3064173D1 (en) Novel 20-0-acylmaytansinoids, process for their preparation and pharmaceutical compositions containing them
IL59914A (en) Esters of acyl-carnitines,process for their preparation and pharmaceutical compositions containing them
EP0029557A3 (en) 7-acylamino-3-substituted cephalosporanic acid derivatives, processes for their preparation, pharmaceutical compositions containing them; their starting compounds and their preparation
IL55429A0 (en) Thiadiaolyl cephalosporin analogs, processes for the preparation thereof,pharmaceutical or veterinary compositions containing the same and method of inhibiting the growth of bacteria therewith
DE3064983D1 (en) 2-acylaminomethyl-1,4-benzodiazepines and their salts, as well as a process for their preparation and pharmaceutical compositions containing these compounds
PH16099A (en) Guanidinothiazole compounds,process for preparing them and medical composition containing them
IL60243A (en) Pharmaceutical compositions containing 4-heteroaroyl and aroylimidazol-2-ones,some novel compounds of this type and their preparation
FR2337143A1 (fr) Procede de preparation de n-phosphonomethylglycine et nouveau produit ainsi obtenu
DE2965279D1 (en) Indanyl derivatives, process for their preparation and pharmaceutical compositions containing these compounds
IL59770A (en) Pharmaceutical compositions containing 3-alkoxy-flavone derivatives,some novel compounds of this type and their preparation
DE3068390D1 (en) Penicillin derivatives, process for their preparation and pharmaceutical compositions containing certain of these compounds
DE2961738D1 (en) N-oxacyclylalkyl piperidines, process for their preparation, pharmaceutical compositions containing these compounds
FR2535969B1 (fr) Compose ether de polyol, son procede de preparation et composition cosmetique le contenant
HUT34318A (en) Process for preparing 3-phenyl-4-cyano-pyrrole derivatives further microbicide compositions containing such compounds as active substances
ES8103112A1 (es) Procedimiento para la obtencion de pseudo-trisacaridos
ZA796386B (en) New process for preparing derivatives of piperidyl-indole,new compound obtained and its salts,their use as medicaments and the pharmaceutical compositions containing them
HUT36099A (en) Pharmaceutical compositions containing process for preparing 4-aroyl-imidazol-2-one derivatives
FR2656865B1 (fr) Compose non ionique iode, son procede de preparation et produit de contraste le contenant.
FR2463121B1 (fr) Derives du 1,1,2-triphenylpropane et du 1,1,2-triphenylpropene, procede de preparation de ces derives et compositions pharmaceutiques contenant ces nouveaux composes
BE892271A (fr) Nouveau compose utile comme medicament antitussif et son procede de preparation
DE3063160D1 (en) Spiro compounds, process for their preparation and pharmaceutical compositions containing them

Legal Events

Date Code Title Description
CC Supplementary protection certificate (spc) laid open to the public (law of 25 june 1990)

Free format text: 92C0208, 920518

CB Supplementary protection certificate (spc) granted (law of 25 june 1990)

Free format text: 92C0208, 791228

CL Concession to grant licences
CP Supplementary protection certificate (spc) filed

Free format text: 93C0062, 930702

CR Request for supplementary protection certificate laid open to the public (eec regulation of 18 june 1992)

Free format text: 93C0062, 930702

CP Supplementary protection certificate (spc) filed
CX Request for supplementary protection certificate (spc) rejected

Free format text: 93C0062, 930702